• Investing
  • Stock
  • Editor’s Pick
  • Economy
The Significant Deals
Stock

Scholar Rock stock surges on positive spinal muscular atrophy treatment data

by October 7, 2024
written by October 7, 2024

Investing.com — Shares of Scholar Rock Holdings skyrocketed 320% on Monday following the announcement of positive results from its Phase 3 SAPPHIRE clinical trial for apitegromab, a treatment for spinal muscular atrophy (SMA).

The trial met its primary endpoint, showing statistically significant improvements in motor function as measured by the Hammersmith Functional Motor Scale Expanded (HFMSE).

Scholar Rock explained in its press release that 30.4% of patients receiving apitegromab experienced a greater than three-point improvement compared to only 12.5% of those on a placebo.

Dr. Jay Backstrom, President and CEO of Scholar Rock, expressed enthusiasm for the results, stating, “The results clearly demonstrate robust and clinically meaningful improvement in motor function in patients with SMA.”

The company plans to submit a U.S. Biologics License Application and European Union marketing authorization application in the first quarter of 2025.

The company added that was no new safety findings were observed in the SAPPHIRE clinical trial and the profile was consistent with that observed in the Phase 2 TOPAZ clinical trial.

Following the news, Truist analysts said in a note that the study showed a clinically meaningful improvement of 1.8 points compared to placebo, reinforcing the unmet need for effective SMA treatments.

They reiterated a Buy rating for Scholar Rock and increased the price target from $20 to $36 per share.

“We see this as a validation of the company’s TGFbeta platform and of their strategy to evaluate anti-myostatin (a drug that improves muscle) on top of a drug that targets the genetic cause of the disease,” said Truist.

“We also see these data as a positive read-through to the company’s obesity program with readout in 2Q2025,” they added. As a reminder, while apitegromab is being evaluated in a Ph2 trial, company plans to develop SRK-439, a next gen anti-myostatin drug that has been engineered specifically for CVD in obesity.”

This post appeared first on investing.com
0 comment
0
FacebookTwitterPinterestEmail

previous post
Greece stocks lower at close of trade; Athens General Composite down 0.57%
next post
NHC says Kirk has become a powerful extratropical cyclone

You may also like

BASF results down on impairments, restructuring

January 27, 2025

Nasdaq futures tumble as China’s AI push rattles...

January 27, 2025

European chipmakers slump as traders gauge DeepSeek AI...

January 27, 2025

China Vanke’s CEO, chairman resign amid growing liquidity...

January 27, 2025

Fuji Media, rocked by sexual misconduct allegations, says...

January 27, 2025

Italy’s MPS shares fall ahead of Mediobanca board...

January 27, 2025

British Land stock drops following stake sale

January 27, 2025

UMG shares rally after new multi-year pact with...

January 27, 2025

BASF shares indicated 3% lower as impairments drag...

January 27, 2025

Ryanair cuts 2026 traffic forecast amid ongoing Boeing...

January 27, 2025
Fill Out & Get More Relevant News








    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Divided Fed proposes rule to ease capital requirements for big Wall Street banks

      June 26, 2025
    • Women’s Tennis Association extends media rights deal with Tennis Channel through 2032

      June 26, 2025
    • Bumble shares jump 26% as dating company plans to axe 30% of workforce

      June 26, 2025
    • Small-business AI use is lagging, but one firm is channeling Sherlock Holmes and knocking out ‘grunt work’

      June 25, 2025

    Categories

    • Economy (245)
    • Editor's Pick (3,646)
    • Investing (534)
    • Stock (6,426)

    Latest News

    • Divided Fed proposes rule to ease capital requirements for big Wall Street banks
    • Women’s Tennis Association extends media rights deal with Tennis Channel through 2032

    Popular News

    • Wall Street futures slip as markets reprice rate path ahead of busy week
    • Canada labor minister to provide update on status of port disputes

    About The Significant deals

    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 thesignificantdeals.com | All Rights Reserved

    The Significant Deals
    • Investing
    • Stock
    • Editor’s Pick
    • Economy